Mesalamine Delayed-Release Tablets, USP 1.2 gram, 120 tablets per bottle, Rx Only, Manufactured b...

FDA Recall #D-0069-2021 — Class II — October 28, 2020

Recall #D-0069-2021 Date: October 28, 2020 Classification: Class II Status: Terminated

Product Description

Mesalamine Delayed-Release Tablets, USP 1.2 gram, 120 tablets per bottle, Rx Only, Manufactured by: Actavis Laboratories, FL, Inc., Fort Lauderdale, FL 33314, Distributed by: Actavis Pharma Inc., Parsippany, NJ 07054, NDC 0591-2245-22.

Reason for Recall

Failed Dissolution Specifications: Out-of-specification dissolution results were obtained during stability testing.

Recalling Firm

Teva Pharmaceuticals USA — Parsippany, NJ

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

133,829 bottles

Distribution

Nationwide in the U.S. and PR

Code Information

Lot #s: 1342498A, Exp. 12/2020; 1342499A, Exp. 01/2021; 1354638A, Exp. 03/2021; 1354639A, 1358274A, 1358448A, 1364618A, 1369884A, Exp. 05/2021; 1366195A, 1369885A, 1373570A, Exp. 06/2021; 1373571A, Exp. 07/2021; 1388571A, Exp. 01/2022; 1395725A, 1396585A, 1397550A, 1399389A, Exp. 04/2022; 1403885A, 1403886A, Exp. 06/2022.

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated